Could This Tiny Biotech Be the Next National Security Play?

A 65% surge. A defense angle. And a drug that could counter fentanyl in bioterror threats.

When’s the last time you got to see a millionaire trader place a live trade—right in front of you?

On Wednesday, August 27th @ 2 P.M. ET, Nate Bear is going live for the very first 10X Lotto Trade Summit.

During this free event, you’ll discover the strategy he used to turn $37K into $2.7M.

You’ll see how he spots low-cost setups that can turn a couple hundred dollars into thousands.

And most importantly, you’ll watch him place a trade live—so you can see how his process works from start to finish.

This isn’t a theory class.

It’s real-world trading, with real setups, and real opportunity.

If you’ve ever wanted to learn how to potentially turn a tiny stake into a meaningful gain—without risking a fortune—this is your chance.

Wall Street fell Monday as rising Treasury yields and caution ahead of fresh inflation data pressured sentiment, though gains in chipmakers like Nvidia and Intel helped limit broader losses.

Royalty Pharma (NASDAQ: RPRX) has agreed to acquire a royalty interest in Amgen’s immunotherapy Imdelltra for up to $950 million.

The deal includes an upfront payment of $885 million to BeOne Medicines and an option for BeOne to sell an additional portion of its royalty for $65 million within the following year.

The royalty covers global net sales of Imdelltra, a recently approved treatment for extensive-stage small cell lung cancer, with rights expected to extend through 2038–2041.

For equity holders, the transaction underscores Royalty Pharma’s strategy of securing exposure to therapies with blockbuster potential.

Imdelltra, which generated $215 million in sales in the first half of 2025 and carries consensus forecasts exceeding $2.8 billion by 2035, provides the company with long-dated cash flow visibility in oncology.

The purchase diversifies Royalty Pharma’s portfolio and reduces reliance on any single therapeutic category.

Prospective entrants can view this as another example of Royalty Pharma using its balance sheet to capture long-term royalties that biopharma companies monetize to fund development pipelines.

By deploying nearly $1 billion into a first-in-class therapy already in the market, the company signals its confidence in sustainable growth across its royalty streams.

The Imdelltra acquisition reinforces Royalty Pharma’s role as a financial leader in life sciences, delivering both diversification and predictable revenue potential for shareholders.

Keurig Dr Pepper (NASDAQ: KDP) announced plans to separate into two standalone companies following its $18 billion acquisition of Peet’s parent, JDE Peet’s.

The restructuring will unwind the 2018 merger between Keurig and Dr Pepper, creating two separate businesses: one focused on coffee and another centered on cold beverages, including Dr Pepper, Snapple, 7UP, and energy drinks.

For investors, the breakup is designed to sharpen strategic focus and unlock value.

The coffee division, bolstered by Peet’s international presence and brands like Jacobs and Douwe Egberts, is expected to generate $16 billion in annual revenue.

This scale positions the company to better compete with global players such as Nestlé and Starbucks, while also diversifying beyond the U.S. single-serve market.

The cold beverage business, with $11 billion in annual sales, gains a platform to accelerate growth in faster-growing categories, such as energy drinks, while offsetting slower volumes in traditional sodas.

By creating two pure-play entities, KDP aims to capture higher valuation multiples and provide investors with clearer exposure to the growth drivers of each category.

This $18 billion Peet’s deal and subsequent split represent a defining shift in KDP’s strategy.

For shareholders, the separation presents an opportunity to benefit from two focused growth platforms while simplifying the combined structure.

Why settle for a “good” year when you could set yourself up for a great one?

Our analysts screened thousands of companies and narrowed them down to 5 stocks with the best chance to double.

These aren’t speculative guesses.

They’re based on:

In the past, this exact report uncovered stocks that soared as much as +175%, +498%, and +673%. ¹

You can get the new report instantly—but only until midnight tonight.

Don’t just play the market. Position yourself to win big.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

The narrative surrounding Johnson & Johnson (NYSE: JNJ) has long been dominated by its legal challenges, yet its market performance tells a different story.

With the stock up more than 23% year-to-date, investors are clearly focused on the company's powerful reinvention as a pure-play medical innovator.

Investors are fixated on Johnson & Johnson's legacy legal risks, overlooking the company's strategic pivot.

This shift has created a more agile enterprise, where a focused portfolio of pharmaceuticals and medical technology (MedTech) is driving impressive growth.

This focus is already yielding results, as evidenced by its Q2 2025 results.

The company's Innovative Medicine segment achieved over $15 billion in quarterly sales, driven by a strong oncology pipeline that is successfully offsetting the anticipated revenue loss from Stelara.

Simultaneously, the MedTech division grew by over 6%, fueled by strategic acquisitions such as Abiomed and Shockwave Medical.

Beyond its growth, J&J offers a rare blend of stability.

As a Dividend King with a 53-year history of increasing payouts, its current 2.91% yield is a testament to its financial discipline.

The company's ability to manage its legal liabilities while aggressively investing in innovation positions it as a premier long-term investment.

For the first time in years, the stock is telling a story that's better than the headlines.

👉 Click here to get our closing report to your cell for free!

Tharimmune Inc [THAR] $7.69 (+63.03%)

Tharimmune continued to rally a few days after releasing positive PK simulation data for TH104, reinforcing its potential as a national security tool against weaponized opioids.

HCW Biologics Inc [HCWB] $5.55 (+60.82%)

HCW Biologics gained after unveiling second-gen immunotherapies designed to enhance checkpoint inhibitors for solid tumors like pancreatic and ovarian cancer.

Sharps Technology Inc [STSS] $10.35 (+40.72%)

Sharps surged after raising $400 million to build what could become the largest Solana treasury, with backing from major crypto VCs like Pantera and CoinFund.

DeFi Development Corp [DFDV] $15.69 (-22.37%)

DeFi Development tumbled after announcing a $125 million equity offering at $12.50, well below its prior $20 trading level, raising dilution concerns despite plans to expand its Solana treasury.

Valneva Se [VALN] $9.43 (-18.50%)

Valneva sank after the FDA suspended the license for its IXCHIQ® vaccine following new serious adverse event reports tied to chikungunya-like illness.

Aether Holdings Inc [ATHR] $6.88 (-15.58%)

Aether declined as Bitcoin slumped over the weekend due to whale-driven selling and macro volatility, pressuring crypto-linked equities.

Market volatility, policy shifts, and economic tension are leaving many investors overwhelmed.

But buried under the chaos are clear signals of opportunity — if you know where to look.

That’s why we created a free, exclusive guide highlighting 7 stocks positioned for growth as 2025 progresses.

This report includes:

Even in uncertain times, preparation separates winners from watchers.

Download your copy today and get one step closer to smarter, faster trades.

[Claim your free report now]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.